Sanara MedTech Inc (NAS:SMTI)

Q3 2025 Sanara Medtech Inc Earnings Call Transcript

Nov 12, 2025 / 01:00 PM GMT

Release Date Price: $21.11 (-24.71%)

Transcript 10-Q8-K8-K

Key Points

Positve

Sanara MedTech Inc (SMTI) achieved a 22% year-over-year growth in net revenue for the third quarter, driven by strong sales of soft tissue repair products.
The company reported a significant improvement in profitability, with a $1 million increase in net income from continuing operations and a $2.3 million improvement in adjusted EBITDA.
Sanara MedTech Inc (SMTI) expanded its network of independent distributors from over 300 to more than 400, enhancing its market reach.
The company published two studies in peer-reviewed medical journals, demonstrating the clinical efficacy of its key products, which helps in educating the medical community.
Sanara MedTech Inc (SMTI) is making progress with its strategic partnership with Biomimetic Innovations Limited, anticipating a US commercial launch of a new product in the first quarter of 2027.

Negative

The decision to cease operations of Tissue Health Plus (THP) was made after failing to find a strategic partner, resulting in a focus shift and potential resource reallocation.
The company anticipates a total cash investment related to THP of $5.5 million to $6.5 million in the second half of 2025, impacting cash flow.
Operating expenses increased by 14% to $21.5 million, driven by higher compensation and marketing expenses.
Interest expenses and fees related to the CRG term loan increased other expenses to $2.1 million, impacting net income.
The company expects a deceleration in revenue growth to high single-digits to low 10s in the fourth quarter, compared to the previous year's exceptional growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SMTI.OQ - Sanara Medtech Inc
Q3 2025 Sanara Medtech Inc Earnings Call
Nov 12, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Senara MedTech 3rd quarter of 2025 earnings conference call.

Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly.

The company issued its earnings release earlier today.

Before we begin, I would like to remind everyone that certain statements on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995. For more information. About the risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements. Please see the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.